Lv4
608 积分 2023-03-26 加入
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
11天前
已完结
Kinase signaling and targeted therapy for primary myelofibrosis
11天前
已完结
First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study
11天前
已完结
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
11天前
已完结
Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study
14天前
已关闭
Food effect trial of the pharmacokinetics and safety of TQ05105 in healthy Chinese subjects
14天前
已完结
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
14天前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
14天前
已完结
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms
14天前
已完结
Combination treatments for myelofibrosis in jak inhibitor-naive patients: evidence, rationale, and clinical direction
14天前
已完结
皖公网安备34019202002308
